AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02035644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo granules
Study NCT01741896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischaemic preconditioning
Description: The intervention is 4 cycles of upper limb ischaemic preconditioning. Each cycle consists of 5 minutes of blood pressure cuff induced ischaemia with 3 minutes of reperfusion. The ischaemic stimulus is induced by inflation of the cuff to 15mmHg above systolic pressure. The reperfusion stimulus is induced by cuff deflation. The RIPC stimulus is commenced at between 30-40 minutes prior to the administration of the IV contrast.
Study NCT03928132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPD Workshop on Depression and Diabetes
Description: 2 parallel face-to-face onsite workshops on diabetes and depression in primary care given by experts in French (control and experimental) using Powerpoint presentations.
Study NCT03928132 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CPD Workshop on Depression and Diabetes
Description: 2 parallel face-to-face onsite workshops on diabetes and depression in primary care given by experts in French (control and experimental) using Powerpoint presentations.
Study NCT01243190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Loading first dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
Study NCT01561404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: In patients that change of immunosuppressive therapy from calcineurin inhibitor (CNI)(tacrolimus or cyclosporine) to m-TOR (everolimus)has been clinically indicated, check if there is an increase in physical exercise capacity.
Study NCT03234699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: 12.5 mg q.d.(Days 13-26), 25 mg q.d. (Days 27-40), 50 mg q.d. (Days 41-54), 100 mg q.d. (Days 55-70), 150 mg q.d. (Days 71-84), 200 mg q.d. (Days 85-110)
Study NCT03234699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: 2 mg midazolam syrup (Days 7, 69, 105)
Study NCT03234699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin Pill
Description: 5 mg (Days 7 and 105)
Study NCT03234699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole Pill
Description: 20 mg (Days 7 and 105)
Study NCT03234699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Pill
Description: 150 mg (Days 1 and 99)
Study NCT03868995 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Dextrose water injection to subcutaneous layer at tender point
Study NCT03868995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tendon injection
Description: Dextrose water injection to injured tendon
Study NCT03600233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVM-1118
Description: Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose).~Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met.
Study NCT03002870 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Patients will receive questionnaires yearly to follow their QOL
Study NCT01822301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeat Fat grafting
Description: Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is considered a standard of care procedure in plastic surgery. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the facial deformity using specialized injection cannulas. In this study, we will treat 5 subjects from protocol (IRB # PRO09060101) with an additional fat graft treatment to assess whether this will increase fat graft retention over time. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101) with be used for comparison.
Study NCT06106932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Leuprolide acetate was administered 3 months before laparoscopy in women of group A.
Study NCT03588286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrophysiology study (EPS)
Description: EPS will be performed in all patients in the intervention arm with programmed ventricular stimulation with a drive train of 8 beats at 400 ms with up to 4 extrastimuli and stimulation from the right ventricular apex with current delivered at twice pacing threshold. The end point for stimulation will be sustained monomorphic ventricular tachycardia (VT) lasting > 10 seconds. If sustained monomorphic VT with cycle length (CL) ≥200ms is induced by ≤4 extra stimuli the EPS result will be considered positive for inducible VT.30 Ventricular fibrillation or flutter with CL\<200ms will be considered a negative result. The Programmed Ventricular Stimulation (PVS) induction will be repeated a second time if the initial induction was negative for VT.
Study NCT03588286 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).
Study NCT03588286 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Magnetic Resonance (CMR)
Description: CMR will be performed on either a 1.5-T or 3-T scanner. Gadolinium contrast (Gd-BOPTA, MultihanceTM) will be administered for quantification myocardial perfusion imaging with subsequent late gadolinium enhanced imaging after a total dose of 0.1mmol/kg. Exclusion criteria specific for CMR will include pregnancy, renal insufficiency defined as glomerular filtration rate (GFR) \<30 mL/min, contraindication to MRI (including non-MRI compatible pacemaker/ICD or metal implants, non-MR safe prosthetic heart valves), claustrophobia which cannot be controlled via standard methods (benzodiazepines and/or sedative antihistamine administration) and prior allergic reaction to gadolinium-based contrast agent.
Study NCT03588286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance (CMR)
Description: CMR will be performed on either a 1.5-T or 3-T scanner. Gadolinium contrast (Gd-BOPTA, MultihanceTM) will be administered for quantification myocardial perfusion imaging with subsequent late gadolinium enhanced imaging after a total dose of 0.1mmol/kg. Exclusion criteria specific for CMR will include pregnancy, renal insufficiency defined as glomerular filtration rate (GFR) \<30 mL/min, contraindication to MRI (including non-MRI compatible pacemaker/ICD or metal implants, non-MR safe prosthetic heart valves), claustrophobia which cannot be controlled via standard methods (benzodiazepines and/or sedative antihistamine administration) and prior allergic reaction to gadolinium-based contrast agent.
Study NCT04793659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Fasudil 90 mg/day
Description: Oral tablet
Study NCT04793659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Fasudil 90 mg/day
Description: Oral tablet
Study NCT04793659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Fasudil 180 mg/day
Description: Oral tablet
Study NCT04793659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Fasudil 180 mg/day
Description: Oral tablet
Study NCT04793659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Oral tablet
Study NCT04793659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Oral tablet
Study NCT00518466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 25 mg modified-release capsules
Study NCT00518466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phentermine
Description: 7.5 mg immediate-release capsules
Study NCT00518466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 100 and 25 mg immediate-release tablets
Study NCT00518466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phentermine
Description: 37.5 and 7.5 mg immediate-release tablets
Study NCT04463173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole
Description: single dose, oral administration 30 minutes after breakfast with high fat food.
Study NCT04463173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole
Description: single dose, oral administration before breakfast.
Study NCT03204188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered daily by mouth starting cycle -3 at 420 mg until end study or disease progression or intolerable side effects occur.
Study NCT03204188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered intravenously only on cycle -2 at 25mg/m\^2 x5 days.
Study NCT03204188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously every 3 weeks at 200 mg starting from cycle 1 through cycle 17 or 1 year of immunotherapy phase.
Study NCT03629639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: An intervention of either metformin or placebo 500mg twice daily plus standard care for 12 weeks. Besides Metformin, standardized topical treatment is given to all patients; For severe psoriasis patients(PASI>8), Methotrexate will be treated orally 7.5mg every week for both the intervention group and the placebo group as a systemic standard care.
Study NCT03629639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: An intervention of either metformin or placebo 500mg twice daily plus standard care for 12 weeks. Besides Metformin, standardized topical treatment is given to all patients; For severe psoriasis patients(PASI>8), Methotrexate will be treated orally 7.5mg every week for both the intervention group and the placebo group as a systemic standard care.
Study NCT01249989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential MBC Condition
Description: Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
Study NCT01249989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simultaneous MBC Condition
Description: Simultaneous MBC condition will target FV+, Sed- and PA+ simultaneously. Participants in the simultaneous condition will wear their accelerometers and enter diet and sedentary activity 5 days/week. All 3 goal thermometers will be activated from the outset of prescription. The goal will be to close 1/3 of the gap between their FV, Sed, and PA statuses and the targets in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain target level behavior changes for FV, Sed and PA through week 12.
Study NCT01249989 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
Study NCT02902874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT02570685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflective Interpersonal Gratitude
Description: Participants were given the following instructions in their journal: Writing is a great way to reflect on your daily events, helping to look back and focus on the good things in our lives. There are many things in our lives, big and small, which we might be grateful for. For the next three weeks, 3 times a week (9 days in total), reflect back on your day and think of the people you met and interacted with and are grateful for. Please write down in the space provided a number of positive social interactions over the day or friendships/relationships you are grateful for.....
Study NCT02570685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflective-Behavioral Gratitude
Description: Participants were given the following identical instructions as the reflective journal in addition to this At the end of each week, express this gratitude to a friend of your choice face-to-face or through e-mail, facebook, a kind note, tell him/her how much you appreciate something specific that he/she does and reflect on how your friend's reaction and how you feel.
Study NCT02570685 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Control Journal
Description: Writing is a great way to reflect on your daily events, helping to look back and reflect on our lives. For the next three weeks, 3 times a week (9 days in total), please write in the spaces provided things that happened during the day.
Study NCT04020354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABIT-ILE
Description: Early Hand and arm bimanual intensive therapy including lower extremities
Study NCT04020354 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual customary care
Study NCT02731573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-PLEX
Description: D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.
Study NCT02731573 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open heart surgery
Description: Subject will undergo open heart surgery according to standard of care
Study NCT01373021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2500mcg+NS50ml
Study NCT01373021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Fentanyl 2500mcg+Dexmedetomidine 500mcg + NS 45ml
Study NCT01456637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for insomnia
Description: The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
Study NCT02458313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMXB-A
Description: 150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
Study NCT02458313 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules b.i.d. for 12 weeks
Study NCT00576706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: Rebamipide 100㎎, 12 weeks
Study NCT00576706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol 200㎍ 12 weeks
Study NCT02012439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy
Study NCT02012439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy
Study NCT02825693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cataract surgery (phacoemulsification)
Study NCT02825693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond laser assisted cataract surgery
Study NCT01043068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cancer pain management
Description: Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
Study NCT02900729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation catheter
Description: Subjects will be treated with the renal denervation procedure using WiseGo Catheter System after randomization.
Study NCT02900729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, losartan potassium and hydrochlorothiazide
Description: Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.
Study NCT02900729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine, losartan potassium and hydrochlorothiazide
Description: Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.
Study NCT02495506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold stored platelets
Description: Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
Study NCT02495506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Room temperature platelets
Description: Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
Study NCT04475458 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound-guided dorsal penile nerve block
Description: This block is performed by the anesthesiologist, after sedation. With an in-plane approach, the tissues around the dorsal penis nerves are visualized. The needle has to pass through Buck's fascia and there the local anesthetic is released.
Study NCT02372604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.
Description: Week 1 to week 5, every day : - the morning : 5 mg of levocetirizine (capsule)~* the evening : placebo capsule~Week 6 to week 10, every day : - the morning : 10 mg of levocetirizine (capsule)~* the evening : 10 mg of levocetirizine (capsule))
Study NCT02372604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.
Description: Week 1 to week 5, every day : - the morning : 10 mg of levocetirizine (tablet)~* the evening : 10 mg of levocetirizine(tablet)~Week 6 to week 10, every day : - the morning : 5 mg of levocetirizine (tablet)~* the evening : placebo tablet